Literature DB >> 3582425

Pharmacokinetics of calcium dobesilate in beagle dogs after a single administration.

C T Plessas, P Karayannakos, S T Plessas, A Costakis, I Donta, G Skalkeas.   

Abstract

A pharmacokinetic study was carried out in beagle dogs after a single intravenous infusion of 100 mg/kg of calcium dobesilate, a dose claimed to produce a cardiac lymphagogue effect. This effect on cardiac lymphatics is known to contribute to the reduction of myocardial infarct size after coronary artery occlusion. At the end of the intravenous infusion, which lasted about 30 minutes, the plasma level was 263 +/- 68 micrograms/ml, falling to 56 +/- 23 micrograms/ml by the third hour. This high plasma level of calcium dobesilate between the end of the infusion and the 3rd hour might explain the pharmacological effect of the drug on the cardiac lymphatic system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3582425     DOI: 10.1007/BF03189115

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  [Metabolism and pharmacokinetics of calcium dobesilate in humans].

Authors:  A Benakis; B Glasson; C A Bouvier; J Ritschard; B Krahenbuhl; A Jung; H J Hachen
Journal:  Therapie       Date:  1974 Mar-Apr       Impact factor: 2.070

2.  Hyperviscosity in whole blood, plasma, and aqueous humor decreased by doxium (calcium dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study.

Authors:  B Vojnikovic
Journal:  Ophthalmic Res       Date:  1984       Impact factor: 2.892

3.  The effects of calcium dobesilate on acute lymphedema (with and without macrophages), and on burn edema.

Authors:  J R Casley-Smith; J R Casley-Smith
Journal:  Lymphology       Date:  1985-03       Impact factor: 1.286

4.  Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy.

Authors:  I S Benarroch; M Brodsky; A Rubinstein; C Viggiano; E A Salama
Journal:  Ophthalmic Res       Date:  1985       Impact factor: 2.892

5.  Prevention of platelet deposition by ibuprofen and calcium dobesilate in expanded polytetrafluoroethylene vascular grafts.

Authors:  P Gloviczki; R J Fowl; L H Hollier; M K Dewanjee; G Plate; M P Kaye
Journal:  Am J Surg       Date:  1985-11       Impact factor: 2.565

6.  Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate).

Authors:  J P Barras; C Graf
Journal:  Vasa       Date:  1980       Impact factor: 1.961

7.  CLS 2210, hyaluronidase and the cardiac lymphatic system.

Authors:  L Szlavy; S Kubik; A de Courten; H J Hachen; F Solti
Journal:  Angiology       Date:  1985-07       Impact factor: 3.619

8.  Influence of a lymphagogue, CLS 2210, on regional cardiac lymphatics and the electrocardiogram after coronary artery occlusion in the dog.

Authors:  L Szlavy; I Repa; A De Courten
Journal:  Lymphology       Date:  1986-03       Impact factor: 1.286

Review 9.  The influence of tissue hydrostatic pressure and protein concentration on fluid and protein uptake by diaphragmatic initial lymphatics; effect of calcium dobesilate.

Authors:  J R Casley-Smith
Journal:  Microcirc Endothelium Lymphatics       Date:  1985-08

10.  Effect of calcium dobesilate and its interaction with aspirin on thrombus formation in vivo.

Authors:  M Michal; N Giessinger
Journal:  Thromb Res       Date:  1985-10-15       Impact factor: 3.944

View more
  2 in total

1.  Pharmacokinetics of calcium dobesilate in beagle dogs after repeated administration.

Authors:  C T Plessas; P Karayannakos; S T Plessas; A Costakis; I Donta; G Skalkeas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

2.  Pharmacokinetic interaction in beagle dogs of antiplatelet drugs: acetylsalicylic acid, dipyridamole and calcium dobesilate.

Authors:  C T Plessas; S Souras; P E Karayannacos; S T Plessas; I Dontas; D Kotsarelis; G Asimakopoulos; J Gogas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.